Business
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12,
About this update from Bridgebio Pharma, Inc.
[{"type":"image","alt":"BridgeBio Pharma, Inc.","displaySize":"","headline":null,"caption":"BridgeBio Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rIWtRfd.HYOh2kEpGfi40w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/67d229c5dfa70aa930ee69ce2872e9be","width":300,"height":47}},"lazy":false},{"type":"text","content":"PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data in individuals with autosomal dominant hypocalcemia type 1 (ADH1) from CALIBRATE, its Phase 3 study of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) taking place in Prague, Czech Republic on May 9-12, 2026. The Company will also share an additional oral presentation, one poster, and one eposter at the meeting.","length":611,"tagName":"p"},{"type":"text","content":"Oral Presentations:Encaleret Restores Mineral Homeostasis in ADH1: Primary Results from the Phase 3 CALIBRATE TrialPresenter: Filomena Cetani, M.D., Ph.D., University of Pisa, ITDate & Time: Tuesday, May 12 at 11:50 am CEST","length":235,"tagName":"p"},{"type":"text","content":"Genetic Testing of Over 400 Individuals with Non-Surgical Hypoparathyroidism Shows Gain-of-Function CASR Variants as the Most Common Genetic Cause IdentifiedPresenter: Arun Mathew, BridgeBio Endocrinology, U.S.Date & Time: Tuesday, May 12 at 12:20 pm CEST","length":261,"tagName":"p"},{"type":"text","content":"Poster:Autosomal Dominant Hypocalcemia Type 1 and Type 2: Baseline Quality of Life Measures in Adult Participants in the CLARIFY Disease Monitoring StudyPresenter: Heide Siggelkow, M.D., University Medical Center of Göttingen, DEPoster ID: P72Date & Time: Sunday, May 10 at 4:55 pm CEST and Monday, May 11 at 5 pm CEST","length":326,"tagName":"p"},{"type":"text","content":"ePoster:Epidemiology and Clinical Management of ADH1: A Systematic Literature ReviewPresenter: Arun Mathew, BridgeBio Endocrinology, U.S.Poster ID: EP260","length":156,"tagName":"p"},{"type":"text","c...